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Background: Esophageal squamous cell carcinoma (ESCC) is a prevalent fatal cancer worldwide, and the number
of deaths due to this disease is increasing. Due to ESCC resistance to chemotherapy and radiation treatment, new
therapies are urgently needed for the improvement of ESCC patient clinical outcomes.
Methods: Eca-109 and TE-1 cells were transfected with 100 nM IGF-1r siRNA, and a combination of IGF-1r siRNA
and radiation therapy was tested in vitro and in vivo. The effects of IGF-1r siRNA were determined through Western
blotting and flow cytometry experiments.
Results: After radiotherapy, the number of IGF-1r siRNA-transfected Eca-109 cells decreased by approximately
67.3%, and a 78.9% reduction was observed in the transfected TE-1 cells. In addition, the Eca-109 and TE-1 cells that
were irradiated following IGF-1r knockdown contained 16.2% and 20.3% apoptotic cells, respectively.
Conclusions: The results of the current study suggest that IGF-1r knockdown may enhance the radiation sensitivity
of ESCC and increase the therapeutic effects of radiation both in vitro and in vivo. These results provide strong
evidence that the targeted application of siRNA will enable the development of new therapeutic strategies for the
clinical treatment of ESCC patients.
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Esophageal squamous cell carcinoma (ESCC), one of the
most common fatal cancers worldwide, is frequently di-
agnosed in China, and the number of deaths due to this
disease is increasing [1-3]. Surgical resection is a stand-
ard treatment for ESCC patients, but its success depends
on the advanced stage and development of the tumor.
Further, chemotherapy and radiotherapy are also trad-
itional therapeutic methods employed for the treatment
of ESCC, often in combination. Unfortunately, although
such multi-therapeutic strategies have been used for the
treatment of ESCC patients, the overall five-year survival
rate remains low at between 10 and 30% [4,5]. In addition,* Correspondence: guxiaomengff@126.com
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unless otherwise stated.the resistance of tumors to radiotherapy and chemother-
apy has also been reported [6-8].
Thus, new therapeutic methods are urgently needed
for the improvement of ESCC clinical treatment. It has
been demonstrated that some pathogenic factors, such
as cancer-related genes, are related to the progression
and development of ESCC. Abnormal gene expression
or modifications including certain genetic or epigenetic
alterations, such as those found in tumor-suppressor
genes or oncogenes, may cause tumor initiation [9,10].
The data suggest that some related tumor genes can also
increase the therapeutic efficacy of ESCC treatment by
improving the chemotherapy or radiation sensitivity of
tumors [11,12]. However, the details and underlying
mechanism of this effect are still unclear.
It was recently reported that insulin-like growth factor
1 (IGF-1), which can bind to IGF-1 receptor (IGF-1r) tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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phosphoinositide-dependent protein kinase-1 (PDK1) and
mammalian targets of rapamycin (mTOR) rictor kinases,
is involved in tumor development, including progression
and angiogenesis. IGF-1 is thus a potential target in cancer
therapy [13-16]. However, whether IGF-1r can modulate
ESCC tumor sensitivity to chemotherapy or radiation
therapy, has not been reported.
Small interfering RNA (siRNA), a recently developed
technology, has been used to disrupt gene expression,
especially of oncogenes or tumor-suppressors, which
regulate target genes [17,18]. However, to date, no evi-
dence has been reported for the combination of radi-
ation therapy and IGF-1r silencing in the treatment of
ESCC. Therefore, IGF-1r siRNA combined with irradi-
ation may be a potential therapeutic option for ESCC
treatment. In the current study, it was hypothesized that
radiation sensitivity will be enhanced after effective in-
hibition of IGF-1r through siRNA gene-silencing tech-
nology, which will result in a higher therapeutic efficacy
in treating ESCC patients.
Methods
Cell lines
The human esophageal cancer cell lines Eca-109 and
TE-1 were obtained from the American Type Culture
Collection (Manassas, Virginia, United States). The cells
were grown in Dulbecco’s modified Eagle’s Medium
(DMEM) supplemented with 10% fetal calf serum (FCS)
and 1% penicillin and streptomycin (Sigma-Aldrich, St.
Louis, Missouri, United States). The cells were passaged
every two to three days to maintain exponential growth
prior to experimental usage and were maintained in 5%
CO2 at 37°C.
siRNA transfection
Eca-109 and TE-1 cells were transfected with 100 nM
IGF-1r siRNA or a negative control vector (Qiagen,
Lafayette, Colorado, United States) using Lipofectamine™
2000 transfection reagent (Invitrogen, Carlsbad, California,
United States) after the above cells were grown to between
75 and 85% confluency to obtain a higher transfection effi-
ciency. After eight hours of transfection, the cell culture
medium was replaced with DMEM. The IGF-1r gene tar-
geting sequences were as follows: 5ʹ-ATTGAGGAGGTCA
CAGAGAAC-3ʹ and 5ʹ-TTCATATCCTGTTTTGGCCTG-3ʹ.
Radiation treatment
After being subjected to IGF-1r siRNA transfection,
which was performed as described above, both the
Eca-109 and TE-1 cells received radiation treatment
with γ-irradiation at a single dose of 4 Gy/min every
three days in the presence or absence of IGF-1r siRNA.Western blotting
Western blotting was used to detect IGF-1r expression
after IGF-1r siRNA transfection for 72 hours to evaluate
the siRNA transfection efficiency in Eca-109 and TE-1
cells. At 24 hours after transfection, the medium was
changed to serum-free medium. After a 72-hour trans-
fection period, the cells were harvested, and cell lysates
prepared in a buffer containing 0.1 M NaCl, 1 mM
EDTA (ethylenediaminetetra-acetate, pH 8.0), 0.01 M
Tris-HCl (pH 7.6), 1% (w/v) NP-40 (Nonidet P-40,
octylphenoxy- polyethoxyethanol), 1% (w/v) Triton X-
100, and 100 mg/ml PMSF(phenylmethanesulfonyl fluor-
ide) (Sigma-Aldrich, St. Louis, Missouri, United States).
Total protein was quantified by a Lowry protein concen-
tration assay (Suolai, Beijing, China) after centrifugation
at 12,000 × g for 60 minutes at 4°C. Equal amounts of
protein were separated by SDS-PAGE and electrically
transferred onto a PVDF (polyvinylidene fluoride) mem-
brane. After blocking, the membrane was incubated over-
night at 4°C with a primary antibody against IGF-1r
(1:1,000; Santa Cruz Biotechnology, Santa Cruz, California,
United States), followed by horseradish peroxidase-
conjugated secondary antibody. The enhanced chemilu-
minescence system ECL-Plus (Suolai, Beijing, China)
was used to detect the immunopositive bands, and the
blot was stripped and re-probed using an antibody
against β-actin (Sigma-Aldrich, St. Louis, Missouri,
United States).
Cell proliferation assay
In the next experiments, cell proliferation was evaluated
by the method of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide. Briefly, Eca-109 and TE-1 cells
were cultured in triplicate in 96-well plates at a density
of 5 × 103 cells/well. The cells were transfected with
IGF-1r siRNA and received the following irradiation
treatment as described above. Cells in each treatment
group were harvested by trypsinization, and the cell
growth was analyzed by a Universal Microplate Spectro-
photometer (BioTek Instruments, Winooski, Vermont,
United States).
Analysis of apoptotic cells by flow cytometry
Eca-109 and TE-1 cells were transfected with IGF-1r
siRNA and received the following irradiation treatment as
described above. Cell apoptosis was evaluated through
staining with propidium iodide and Annexin V-FITC using
flow cytometry (Becton Dickinson, San Jose, California,
United States).
In vivo tumor xenograft studies
An animal model with subcutaneous tumor xenografts
was established by injecting Eca-109 and TE-1 cells into
the left dorsal flank (1 × 105 cells per animal) of female
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University, Jinan, China). After 14 days, the above ani-
mals received the irradiation treatment in the presence
or absence of IGF-1r siRNA transfection. Student’s t-test
was used to determine the statistical significance of the
therapeutic effects. All procedures were approved by
the Animal Ethics Committee of Shandong University
(QL-2012JMK-231).
Results
Evaluation of IGF-1r siRNA transfection efficiency
Western blotting was used to test the expression level of
IGF-1r to evaluate the transfection efficiency of the IGF-1r
siRNA. It was confirmed that the expression of IGF-1r de-
creased by approximately 33% and 46% in the Eca-109 and
TE-1 cells, respectively, after IGF-1r siRNA transfection for
72 hours. In addition, a difference in IGF-1r expression
between Eca-109 and TE-1 cells was also observed,
with IGF-1r expression being much higher in TE-1 cells
than in Eca-109 cells (Figure 1A).
Furthermore, the IGF-1r siRNA transfection efficiency
was also evaluated with green fluorescence analysis using
a fluorescence microscope (OLYMPUS, Tokyo, Japan).
The results showed that the level of green fluorescence
was greatly increased, which confirmed that effective
transfection was obtained after 72 hours of siRNA trans-
fection both in Eca-109 and TE-1 cells (Figure 1B).
Effective inhibition of cell proliferation after combination
treatment
To evaluate the effect of radiotherapy on cell prolifera-
tion in the presence or absence of IGF-1r siRNA trans-
fection in vitro, the cell proliferation of Eca-109 and TE-
1 cells was determined in the following experiment. The
control group was treated with IGF-1r siRNA or with ra-
diation alone. The controls were compared to cells receiv-
ing a combination of γ-irradiation therapy of 4 Gy/min
and IGF-1r siRNA transfection for 72 hours. BothFigure 1 Transfection efficiency of IGF-1r siRNA in vitro.
(A) IGF-1r protein expression was analyzed by Western blotting after
transfection with IGF-1r siRNA for 72 hours in TE-1 and Eca-109 cells.
(B) The transfection efficiency of IGF-1r siRNA was observed by
fluorescence microscopy after 72 hours in TE-1 and Eca-109 cells.
β-actin was used as a loading control.radiation and IGF-1r siRNA can effectively inhibit cell
proliferation alone, with radiation reducing the cell counts
by 42.1% and 45.1% and IGF-1r siRNA reducing them by
36.5% and 43.1% in Eca-109 and TE-1 cells, respectively,
compared to the untreated group (P <0.05, n =6). For the
group receiving the combination therapy, the inhibition of
cell proliferation was also more effective than that in the
control group for both Eca-109 and TE-1 cells (P <0.001,
n =6). After radiotherapy, the number of Eca-109 cells de-
creased by approximately 67.3% in the presence of IGF-1r
siRNA transfection, and there was a 78.9% reduction in
the TE-1 cells after radiation (Figure 2). In the TE-1 cells,
the inhibition of cell proliferation after IGF-1r siRNA
transfection was much higher than in the Eca-109 cells
(P <0.01, n =6); this difference may result from the dif-
ferent expression levels of IGF-1r in these two cell lines.
These results also show that the inhibition of cell pro-
liferation after IGF-1r siRNA or radiation treatment
alone was lower than in the combination treated group.
Effects of combination treatment on apoptosis
To test the effect of IGF-1r knockdown on Eca-109 and
TE-1 cell apoptosis, flow cytometry was used to investi-
gate the percentage of apoptotic cells. The percentage of
apoptosis was 11.2 ± 0.8% after irradiation alone in Eca-
109 cells. In the combination group, 16.2 ± 1.1% apoptotic
Eca-109 cells were observed after irradiation coupled with
IGF-1r siRNA treatment. In the TE-1 cells, 13.1 ± 1.1%
apoptotic cells were observed after irradiation alone, and
20.3 ± 2.1% apoptotic cells were observed in the presence
of IGF-1r siRNA treatment following irradiation, respect-
ively (Figure 3). This result also suggests that some differ-
ences in apoptosis were observed between the Eca-109
and TE-1 cells (P <0.01, n =6), and these data were also
consistent with the results that showed a lower expression
of IGF-1r in Eca-109 cells than in TE-1 cells. Furthermore,
it was clear that the percentage of apoptotic cells increased
significantly after combination treatment compared to the
cells that only received radiation (P <0.01, n =6).
Effects of combination therapy on subcutaneous tumor
growth
The therapeutic efficacy of combination treatment was
also investigated through in vivo tumor xenograft stud-
ies after injecting Eca-109 and TE-1 cells. The tumor
volumes and survival rates were evaluated 14 days after
cell injection in the different treated groups. The tumor
volumes were 3.4 ± 0.2 cm3 in the Eca-109 group and
3.8 ± 0.1 cm3 in the TE-1 group after treatment with
phosphate buffered saline (negative control group). After
radiotherapy alone, the tumor volume decreased signifi-
cantly both in the Eca-109 (2.1 ± 0.1 cm3) and TE-1 cells
(2.4 ± 0.1 cm3) (P <0.05, n =8). In the group that re-
ceived IGF-1r siRNA treatment alone, the tumor volume
Figure 2 Effect of combination therapy on the growth of esophageal squamous cell carcinoma cell lines in vitro. (A, B) Cell proliferation
of Eca-109 cells was influenced after γ-irradiation at 4 Gy/min (IR) in the presence or absence of IGF-1r siRNA. (C, D) Cell proliferation of TE-1 cells
was influenced after γ-irradiation at 4 Gy/min (IR) in the presence or absence of IGF-1r siRNA. Bars indicate the standard deviation of the mean.
Each experiment was performed in triplicate. (The criterion for statistical significance was *, ** and *** as p < 0.05, 0.01 and 0.001, respectively).
Figure 3 Effect of combination therapy on apoptosis in TE-1
and Eca-109 cells. (A) Eca-109 and (B) TE-1 cells were γ-irradiated
at 4 Gy/min in the presence or absence of IGF-1r siRNA and then
evaluated by flow cytometry. Bars indicate the standard deviation of
the mean. Each experiment was performed in triplicate.
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0.1 cm3 for TE-1 cells) (P <0.05, n =8). Notably, it was
clear that the tumors were much smaller after irradiation
in the presence of IGF-1r siRNA transfection than in
any single treatment group (1.1 ± 0.2 cm3 in the Eca-109
group; 0.8 ± 0.1 cm3 in the TE-1 group) (P <0.001, n =8)
(Figure 4A). In addition, the survival rates of the tumor-
bearing mice were also calculated after different thera-
peutic strategies. The results showed that the combination
therapy significantly enhanced the survival rate compared
to the groups with a single treatment (Figure 4B). These
in vivo results confirmed that IGF-1r silencing can in-
crease the radiation sensitivity of ESCC tumors in this
established tumor model.
Discussion
It has been reported that radiation resistance can reduce
the therapeutic efficiency of irradiation in clinical ESCC
tumor treatments, and thus, a new method that can
increase the radiation sensitivity of tumor therapies is
urgently needed to enhance the survival rate of ESCC
patients. Overexpression of IGF-1r in tumors has been
demonstrated in some reports [19,20], so to test the
Figure 4 Therapeutic effect of irradiation combined with IGF-1r siRNA in vivo. The survival fraction after treatment is shown for (A) Eca-109
and (B) TE-1 cells, respectively. Irradiation alone enhanced tumor growth inhibition and led to shorter survival times than the combination
treatment. The tumor volume was calculated at the indicated times in the (C) Eca-109 and (D) TE-1 cell groups, respectively. The statistical
significance of the tumor volume changes was calculated using Student’s t-test.
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peutic efficacy of radiotherapy in the treatment of ESCC,
a combination of IGF-1r siRNA and radiation therapy
was tested in vitro and in vivo.
The following novel findings were demonstrated in
our current study: (1) higher IGF-1r expression was ob-
served in human TE-1 cells than in Eca-109 cells; (2) ef-
fective inhibition of cell proliferation and apoptosis in
the presence of IGF-1r siRNA following radiotherapy
was demonstrated in vitro; and (3) enhancement of
tumor growth radiation sensitivity after IGF-1r siRNA
treatment was observed in vivo. Thus, we demonstrated
that greater therapeutic efficacy may be obtained by en-
hancing the sensitivity of tumors to radiotherapy in the
presence of IGF-1r siRNA knockdown.
It was shown that higher IGF-1r expression was observed
in human TE-1 cells than in Eca-109 cells, and the data
suggested that IGF-1r deficiency can be obtained effectively
in the above cell lines using the siRNA silencing method
and that this method can be used to evaluate the effects of
IGF-1r modulation on radiotherapy treatment. Results
from both Western blotting and fluorescence microscopy
demonstrated that effective IGF-1r siRNA transfection hadbeen achieved in TE-1 and Eca-109 cells. However, differ-
ent levels of IGF-1r expression were also observed in these
cell lines, and the divergence of IGF-1r expression in these
two cell types may explain the different clinical pathology
characteristics of ESCC.
The therapeutic efficacy of irradiation on cell prolifer-
ation was dramatically enhanced in the presence of
IGF-1r siRNA application in vitro, and this effect on
the inhibition of cell proliferation was higher than the
effect after radiation therapy alone. Cell apoptosis was
also investigated to evaluate the effect of IGF-1r siRNA
on cell sensitivity to irradiation. The effect of radiation
therapy on cell apoptosis was also modulated after
transfection with IGF-1r siRNA in TE-1 and Eca-109
cells, and a significant enhancement in the percentage
of apoptotic cells was observed after combination ther-
apy. An animal tumor model was established by sub-
cutaneously injecting TE-1 or Eca-109 cells to test the
anti-tumor effects of radiation therapy in vivo in the
presence or absence of IGF-1r siRNA. Compared to the
combination therapy group, larger tumor sizes and
lower survival rates were obtained after radiation ther-
apy in the absence of IGF-1r siRNA treatment. These
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radiation sensitivity, but the underlying mechanism requires
further investigation.
The in vivo and in vitro data clearly showed that the
combination therapy had greater anti-tumor therapeutic
efficacy in both the TE-1 and Eca-109 cells due to the
enhancement of tumor radiation sensitivity in the pres-
ence of IGF-1r siRNA. Differences between the expres-
sion of IGF-1r in the TE-1 and Eca-109 cells were also
observed, and these characteristics may affect the differ-
ent responses to radiation treatment in ESCC patients
with different pathological cell types.
Conclusions
The current study demonstrated that IGF-1r siRNA,
which can effectively reduce IGF-1r expression in both
TE-1 and Eca-109 cells, may enhance the radiation sen-
sitivity of ESCC tumors and increase the therapeutic ef-
fects of radiation both in vitro and in vivo. These results
provide strong evidence that targeted use of siRNA may
enable the development of new therapeutic strategies for
the clinical treatment of ESCC patients.
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